Region - North America, Latin America, Europe, Asia Pacific, Middle East & Africa, Japan,
In 2015, the first Oncolytic virus immunotherapy was approved, and Oncolytic Immunotherapy represents a new and an exciting area of cancer therapy. Oncology Immunotherapy exploits virus’s ability to replicate selectively and kill tumor tissue while at the same time regulate the specific immune response of a patient The first oncolytic virus to demonstrate a clinical benefit in patients with melanoma is genetically modified herpes simplex virus type I i.e. Talimogene laherparepvec (T-VEC).
Nearly 48 oncolytic virus therapy are in clinical trial. The purpose of developing a new therapy for the treatment of cancer is because of the side-effects caused by conventional chemotherapy and radiotherapy.
Imlygic is an advanced therapy medicine used to treat adults with melanoma which cannot be treated surgically and has spread to the other parts of the body but no to lung, brain or bone. It is available as a solution in two different strength and the volume to be injected depends on the number and size of the tumors to be injected.
The most common serious side effects of oncolytic virus immunotherapy are cellutus.
The past decades have shown the higher prevalence and incidence for melanoma, and globally, the scenario is worsening with the increase in a number of patients with cancer. Development of new therapy i.e.
oncolytic virus immunotherapy for melanoma is to have higher potency towards the malignant cells with no or low toxic effect as compared to other conventional and chemotherapy. These are the possible drivers for the growth of oncolytic virus immunotherapy market.
Other drivers such as an increase in global warming affecting the skin, aggressive marketing strategies along with huge investment in research and development for the development of treatment methods had led to significant increase in oncolytic virus immunotherapy. challenges are faced by researchers in developing oncolytic virus as a new class of anti-cancer immunotherapy, so it requires more practical clinical trials design and assessment criterion, as well as the costly nature of cell lines and irreplaceable samples, are restraining the oncolytic virus immunotherapy market.
. There are seven main categories in which Current immunotherapy approaches for melanoma fall: oncolytic virus therapies checkpoint inhibitors, cancer vaccines, adjuvant immunotherapy monoclonal antibodies, adoptive cell therapy, and cytokines. To increase the effectiveness of oncolytic virus therapy and broaden its applicability is an aim of the ongoing research.
A phase I clinical trial of Cavatak™, Toca 51 and GL-ONC1 are oncolytic virus immunotherapy drug for melanoma.
For more information on this report, fill the form @ www.persistencemarketresearch.com/samples/15262
North America is leading in the oncolytic virus immunotherapy market globally, according to Skin Cancer Foundation Statistics, Globally 132,000 melanoma skin cancers occur each year. One in every three cancers diagnosed is a skin cancer, and one in every five Americans will develop skin cancer in their lifetime.
North America has well-developed healthcare infrastructure with massive investment in research and development of oncolytic virus immunotherapy.
Imlygic, an oncolytic virus immunotherapy drug, is marketed by Amgen Inc., but however several other competitors are expected to enter in oncolytic virus immunotherapy in the forecast period.
Category: Market Research Publishers and RetailersCompany about: Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intel ...